Details: pack, label wording, sources, registration
Rometar 20 mg/ml, Solution
xylazine 20 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Label-concordant IM sedation and anaesthetic premedication in appropriately selected dogs, with balanced analgesia for painful procedures
6.7/10
Situational / acceptable
Details →
vetman assessment
Rometar
×
20 mg/ml, xylazine 20 mg/ml, solution for injection
Assessed clinical scope Dog · Label-concordant IM sedation and anaesthetic premedication in appropriately selected dogs, with balanced analgesia for painful procedures · Intramuscular
Care setting Veterinary-only administration after pre-anaesthetic assessment, exact weight/concentration calculation and protocol reconciliation; airway, oxygen, cardiovascular/ventilation/temperature monitoring and supervised recovery immediately available
vetman score
6.7/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, veterinary · Verified on 22 Oct 2026
An effective authorised canine sedative with a clear exact dose, but not a benign or complete anaesthetic. Its cardiovascular/respiratory burden and older protocol make careful selection, balanced analgesia and full monitoring decisive.
Regulatory and scientific credibility 8.0/10
The exact 50 ml product has current Czech and Georgian veterinary registration, regulator-visible identity and a transparent exact instruction; separate Slovak authorisation and current same-strength controls support class applicability. The legacy dossier and limited exact-product outcome/pharmacovigilance publications cap the score.
Clinical efficacy 7.0/10
Xylazine reliably produces dose-dependent canine sedation and muscle relaxation, and direct physiologic studies confirm effect. Responses vary, modern guidance often prefers more selective alpha-2 agonists, and xylazine alone does not supply dependable surgical analgesia.
Safety and tolerability 5.0/10
Clinically important bradycardia/AV block, biphasic blood pressure, reduced cardiac output, arrhythmia, respiratory depression, emesis, hypothermia, hyperglycaemia and rare arrest require strict selection and monitoring. Airway disease, shock, cardiac/respiratory/hepatic/renal disease, diabetes, seizures and GI obstruction are hard exclusions.
Clinical practicality 7.0/10
A single IM injection and familiar 20 mg/ml concentration are operationally simple, but 0.05–0.15 ml/kg must be measured accurately and cannot be titrated IV on this exact label. Pre-assessment, fasting plan, combination-dose reduction, monitoring and recovery staffing are substantial requirements.
Full-course cost-effectiveness -
Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.
Important safety and use flags
Use only after examination in a monitored veterinary setting with oxygen, airway/ventilation and cardiovascular resuscitation capability. Record exact weight, concentration, route, total dose, co-drugs and times. Do not use with GI obstruction, significant cardiac disease or ventricular arrhythmia, respiratory insufficiency, hepatic/renal impairment, seizure history, hypotension/shock or diabetes; avoid in puppies/kittens under six weeks. Exact dose is 1–3 mg/kg IM once; there is no dog IV dose on this Rometar label. Use the lowest effective dose, especially in older, obese, large or compromised dogs, and do not automatically give the printed one-third to one-half top-up. Monitor ECG/rhythm, heart rate, blood pressure, oxygenation, ventilation, temperature and sedation depth continuously through recovery. Bradycardia/AV block can be severe, and an initial pressure rise may be followed by hypotension and reduced cardiac output. Vomiting commonly occurs within minutes. Use an individual fasting plan, protect the airway and position/recover the patient to reduce regurgitation and aspiration risk; fasting does not eliminate that risk. Xylazine alone is not reliable surgical analgesia or general anaesthesia. For painful procedures provide local/general anaesthesia and multimodal analgesia, reducing all interacting sedative/anaesthetic doses to effect. Other CNS depressants are additive. Do not combine with epinephrine or other sympathomimetics because ventricular arrhythmia may follow; reconcile every co-drug and avoid casual protocol substitution. Brachycephalic airway disease can cause life-threatening dyspnoea; deep-chested breeds may bloat. Pregnancy requires benefit–risk assessment and late-pregnancy use is contraindicated except at parturition. An alpha-2 antagonist may reverse selected effects but does not erase aspiration, hypoxaemia, arrhythmia, temperature, fluid or co-anaesthetic risk. Calculate the antagonist protocol and continue monitoring for pain, haemodynamic change or re-sedation. Prevent accidental self-injection, ingestion and skin/eye/mucosal exposure. After exposure seek urgent medical advice and do not drive; pregnant handlers need special caution. Store below 25°C, protect from light and discard 28 days after opening. Assessment sources +
Close
Cat
Label-concordant IM or SC sedation and anaesthetic premedication in appropriately selected cats, with balanced analgesia for painful procedures
6.4/10
Situational / acceptable
Details →
vetman assessment
Rometar
×
20 mg/ml, xylazine 20 mg/ml, solution for injection
Assessed clinical scope Cat · Label-concordant IM or SC sedation and anaesthetic premedication in appropriately selected cats, with balanced analgesia for painful procedures · IM,SC
Care setting Veterinary-only administration after pre-anaesthetic assessment, exact weight/concentration calculation and protocol reconciliation; airway, oxygen, cardiovascular/ventilation/temperature monitoring and supervised recovery immediately available
vetman score
6.4/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, veterinary · Verified on 22 Oct 2026
An authorised effective feline sedative whose frequent emesis, respiratory/cardiovascular burden and small-volume dosing make it a conditional monitored option rather than a routine default.
Regulatory and scientific credibility 8.0/10
The exact 50 ml product has current Czech and Georgian veterinary registration, regulator-visible identity and a transparent exact instruction; separate Slovak authorisation and current same-strength controls support class applicability. The legacy dossier and limited exact-product outcome/pharmacovigilance publications cap the score.
Clinical efficacy 6.5/10
Authorised exact labeling and established alpha-2 pharmacology support feline sedation, but direct modern feline clinical-outcome evidence is thinner and response at the exact upper dose includes respiratory depression. It is premedication, not complete anaesthesia or stand-alone surgical analgesia.
Safety and tolerability 4.5/10
Frequent onset emesis plus bradycardia/AV block, pressure and cardiac-output change, respiratory depression at the upper label dose, hyperglycaemia, hypothermia, polyuria and rare arrest create a narrow safety margin. Late pregnancy also carries a specific uterine/premature-labour hazard.
Clinical practicality 6.5/10
A single IM/SC injection is simple, but a 0.05–0.1 ml/kg volume can be very small and handling plus vomiting/airway preparation matter. Individual fasting, combination-dose reduction, continuous monitoring and full supervised recovery limit convenience despite one administration.
Full-course cost-effectiveness -
Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.
Important safety and use flags
Use only after examination in a monitored veterinary setting with oxygen, airway/ventilation and cardiovascular resuscitation capability. Record exact weight, concentration, route, total dose, co-drugs and times. Do not use with GI obstruction, significant cardiac disease or ventricular arrhythmia, respiratory insufficiency, hepatic/renal impairment, seizure history, hypotension/shock or diabetes; avoid in puppies/kittens under six weeks. Exact dose is 1–2 mg/kg IM or SC once; the upper limit may depress respiration. Measure the small volume accurately, use the lowest effective dose and do not automatically give the printed one-third to one-half top-up. Monitor ECG/rhythm, heart rate, blood pressure, oxygenation, ventilation, temperature and sedation depth continuously through recovery. Bradycardia/AV block can be severe, and an initial pressure rise may be followed by hypotension and reduced cardiac output. Vomiting commonly occurs within minutes. Use an individual fasting plan, protect the airway and position/recover the patient to reduce regurgitation and aspiration risk; fasting does not eliminate that risk. Xylazine alone is not reliable surgical analgesia or general anaesthesia. For painful procedures provide local/general anaesthesia and multimodal analgesia, reducing all interacting sedative/anaesthetic doses to effect. Other CNS depressants are additive. Do not combine with epinephrine or other sympathomimetics because ventricular arrhythmia may follow; reconcile every co-drug and avoid casual protocol substitution. Do not use in late pregnancy because uterine contraction and premature labour may occur; earlier pregnancy requires explicit benefit–risk assessment. Anticipate hyperglycaemia and polyuria, especially when metabolic status matters. An alpha-2 antagonist may reverse selected effects but does not erase aspiration, hypoxaemia, arrhythmia, temperature, fluid or co-anaesthetic risk. Calculate the antagonist protocol and continue monitoring for pain, haemodynamic change or re-sedation. Prevent accidental self-injection, ingestion and skin/eye/mucosal exposure. After exposure seek urgent medical advice and do not drive; pregnant handlers need special caution. Store below 25°C, protect from light and discard 28 days after opening. Assessment sources +
Close
Composition / strength
Xylazine 20 mg/ml
Administration route
Intramuscular, Subcutaneous
Registration
Georgia
Yes, veterinary
Veterinary (National Food Agency)
In the register: რომეტარი 20მგ/მლ
Verified on: 22 Oct 2026
EU
Yes, veterinary
№ 99/192/85-C
Verified on: 22 Oct 2026
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified
Veterinarian-administered sedation/premedication. Dog: 1–3 mg/kg IM once. Cat: 1–2 mg/kg IM or SC once; the upper limit may depress respiration. Use the lowest effective dose after examination; do not automatically top up. Painful procedures need local/general anaesthesia and multimodal analgesia. Plan fasting, anticholinergic use, airway support and recovery monitoring for the individual patient.
Cat
Weight Sedation · Subcutaneous / Intramuscular
Any weight
1–2 mg/kg
Sedation · Subcutaneous / Intramuscular (once; top-up 1/3-1/2 of the first dose): Exact Rometar dose: 1–2 mg/kg (0.05–0.1 ml/kg) IM or SC once; the upper exact-label limit may depress respiration. Use the lowest effective dose and do not automatically repeat. Fasting and anticholinergic use require a current patient/procedure-specific plan.
Source:
Rometar Czech SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Rometar 20 mg/ml solution for injection - current Czech authorisation and SPC
EU Veterinary Medicines Information / Czech USKVBL, 2026
Dog
Weight Sedation · Intramuscular
Any weight
1–3 mg/kg
Sedation · Intramuscular (once; top-up 1/3-1/2 of the first dose): Exact Rometar dose: 1–3 mg/kg (0.05–0.15 ml/kg) IM once. Use the lowest effective dose and do not automatically repeat; reassess depth, physiology and co-administered depressants. The exact label has no IV dog dose. Fasting and anticholinergic use require a current patient/procedure-specific plan.
Source:
Rometar Czech SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Rometar 20 mg/ml solution for injection - current Czech authorisation and SPC
EU Veterinary Medicines Information / Czech USKVBL, 2026
